Spark Therapeutics is engaged in the field of gene therapy. Co. has built a pipeline of gene therapy product candidates that are directed to the retina, the liver and the central nervous system. Co.'s product, LUXTURNA (voretigene neparvovec-rzyl), has been approved by the U.S. Food and Drug Administration for the treatment of patients with viable retinal cells and confirmed biallelic RPE65 mutation-associated retinal dystrophy. Co.'s gene therapy product candidates in clinical development include: SPK-8011, Co.'s primary product candidate in the SPK-FVIII program for hemophilia A; SPK-8016, a product candidate for the hemophilia A inhibitor market; and SPK-7001, targeting choroideremia. The ONCE stock yearly return is shown above.
The yearly return on the ONCE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ONCE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|